Atopic Dermatitis

Upadacitinib exhibited efficacy and a favorable benefit-risk profile for the long-term treatment of moderate to severe atopic dermatitis in adolescents, according to a study.

Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis, according to a study.

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio Dermatology Chief Medical Editor, discusses hot topics in the field with leading experts.

BOSTON — Patients with moderate to severe atopic dermatitis experienced relief with lebrikizumab for 52 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

A study on cancer-causing benzene in acne products was Healio Dermatology’s most-read article of October, with coverage from clinical meetings also garnering attention.

Dermavant Sciences presented full results from its long-term extension trial of Vtama cream 1% for the treatment of atopic dermatitis at the Fall Clinical Dermatology Conference, the company announced in a press release.

LEO Pharma presented full results from its long-term trial of Adbry for atopic dermatitis at the Fall Clinical Dermatology Conference, according to a company press release.

BOSTON — Work from four of the six winners of a grant from the Allergists’ Foundation as part of the Community Grant Program focus on asthma, according to an American College of Allergy, Asthma & Immunology press release.

BOSTON — About one-third of children with atopic dermatitis saw mild improvements with elimination diets, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.